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Abstract
Background Multiple daily dosing may be negatively
associated with patient medication adherence; however,
adherence-related data are lacking in a patient population
with venous thromboembolism (VTE).
Objective To assess the adherence rates between once-
daily (OD) and twice-daily (BID) dosing regimens of
chronic medications in patients with VTE.
Methods We analyzed the PharMetrics Integrated Claims
database (claims of commercial insurers in the US) from 1
January 2004, through 31 December 2009. Adult patients
with continuous insurance coverage, newly initiated on
diabetes mellitus or hypertension medication, and having at
least one VTE diagnosis were included. Adherence to OD
and BID therapies was calculated by using two measures:
medication possession ratio (MPR) and proportion of days
covered (PDC). Adherence was defined as an MPR or PDC
C0.8. Multivariate logistic regressions were conducted to
compare the probability of adherence between the OD and
BID groups adjusting for baseline confounders.
Results A total of 4,867 OD and 1,069 BID patients were
identified. Mean duration of exposure to therapy for OD and
BID patients was 386 and 356 days (p = 0.011), respectively.
Based on MPR, 69 % of OD and 62 % of BID patients were
adherent (p \ 0.001). For PDC at 12 months, the proportion
of adherent patients for the OD and BID groups was 45 and
36 % (p \ 0.001), respectively. Adjusted odds ratios (95 %
CI) of adherence for the OD relative to BID group were 1.61
(1.37–1.89) based on MPR (p \ 0.001) and 1.46 (1.16–1.83)
based on PDC at 12 months (p = 0.001).
Conclusions This study demonstrates that VTE patients
treated with chronic medications on OD dosing regimens
were associated with an approximately 39–61 % higher
likelihood of adherence compared with subjects on BID
dosing regimens.
Key Points for Decision Makers
• Prior to the current study, no other study had evaluated
the relationship between medication adherence and
daily dosing in patients with venous thromboembolism
(VTE), and due to short half-lives, some medications
used to treat VTE patients require strict adherence
• This study shows that VTE patients treated with once-
daily dosing regimens for chronic medications were
associated with an approximately 39–61 % higher
likelihood of adherence compared with subjects on
twice-daily regimens
1 Introduction
Adherence to chronic medications has been described in
the general population [1]; however, no study has evaluated
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the relationship between medication adherence and daily
dosing in patients with venous thromboembolism (VTE).
Due to short half-lives, some medications used to treat
VTE patients require strict adherence; hence, the topic is
especially relevant in this population [2–4].
VTE, which comprises deep vein thrombosis (DVT) and
pulmonary embolism (PE), is a major health problem with
approximately 900,000 incident cases annually in the
United States (US), including 600,000 occurring in the
hospital [5]. Almost 300,000 deaths annually have been
attributed to PE in the US [5]; 2–10 % of all hospital deaths
are associated with PE [6, 7] and up to 25 % of all PE cases
result in sudden death [8, 9]. VTE patients are also at high
risk of developing complications such as VTE recurrence,
post-thrombotic syndrome, and chronic thromboembolic
pulmonary hypertension.
Recent meta-analyses [10, 11] have assessed the associa-
tion between adherence and daily dose frequency for once-
daily (OD) versus twice-daily (BID) regimens, reporting a
7–23 % higher adherence for OD versus BID regimens, but
data specific to VTE patients are lacking. Studies have also
shown that treatment adherence is an important consideration
for VTE patients. It has been estimated that nearly a quarter of
patients receive anticoagulant therapy for less than the rec-
ommended length of time after hospital discharge and that
12 % of patients discontinue within 3 months [12, 13].
Moreover, given the unique comorbidity profile of the VTE
population (e.g., many subjects had a prior surgery or other
risk factors such as cancer, infections, chronic heart failure,
and chronic lung disease) [14–18], and the severity of a VTE
event and its possible complications, the assessment of
adherence to OD and BID regimens for this specific popula-
tion is of particular interest considering the common use of
chronic medications for VTE patients. To fill this gap in the
literature, the current study compares real-world adherence
rates between OD and BID antidiabetics and antihyperten-
sives in patients with VTE.
2 Patients and Methods
2.1 Data Source
Health insurance claims from the PharMetrics database
between 1 January 2004, and 31 December 2009, were
used to conduct the analysis. The PharMetrics Integrated
Database is the largest nonpayer-owned integrated claims
database of commercial insurers in the US. This de-iden-
tified, integrated database includes medical and pharmacy
claims for more than 55 million unique members from
more than 90 health plans across the US. Data elements
include inpatient and outpatient claims, diagnoses and
procedures based on ICD-9 and CPT-4 codes, as well as
retail and mail order pharmacy claims. The records in the
PharMetrics Integrated Database are representative of the
national commercially insured population and include a
variety of demographic measures such as age, gender, and
plan type. This longitudinal data has an average member
enrollment period of 2 years [19].
2.2 Study Design
A retrospective longitudinal cohort design was used where
adult patients with VTE initiating an oral OD or BID regimen
of antidiabetic or antihypertensive medications were identi-
fied. To be included in the study sample, patients were
required to meet the following criteria: (a) have at least two
OD or BID dispensings of antidiabetics, antihypertensives,
calcium channel blockers, diuretics, or other hypertension
medications, (b) be at least 18 years of age at the index date,
(c) have at least 180 days of continuous enrollment before the
index date (baseline period), and (d) have at least one primary
or secondary diagnosis of VTE (ICD-9-Clinical Modification
[CM] codes 451.1x, 451.2, 453.4x and 453.9 [DVT], and
415.1x [PE]) during the baseline period. No diagnosis of
diabetes or hypertension was required. VTE patients with any
other antidiabetic or antihypertensive medications (e.g., three
times daily (TID), four times daily (QID), or from any other
route of administration) during the 180-day baseline period or
patients initiated on both OD and BID medications at the index
date were excluded.
The observation period of patients spanned from the
index date through the earliest date between a switch to an
agent in another drug class (e.g., switch from a biguanide
antidiabetic agent to a sulfonylureas antidiabetic agent),
health plan disenrollment, and end of data availability (31
December 2009). Using an intent-to-treat approach (ITT),
switches from the initial agent to another agent inside the
same drug class were permitted regardless of the daily
dosing frequency of the new agent the patient switched to.
2.3 Definition of Medication Adherence
and Persistence
Adherence to OD and BID dosing regimens was estimated
using the medication possession ratio (MPR) and the pro-
portion of days covered (PDC). The MPR measure assessed
the days of supply (i.e., the number of days a prescription is
supposed to last) of each dispensing with the entire expo-
sure to the treatment. The exposure to therapy was defined
as the number of days between the date of the first drug fill
and that of the last drug refill, plus the number of days of
supply of that last refill. The MPR was then defined as the
sum of the medication days of supply divided by the
exposure to therapy [20]. The PDC differs from the MPR
by being measured over fixed periods of time, namely 3, 6,
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12, and 18 months for this study. The PDC was calculated
as the sum of the medication days of supply divided by the
number of days evaluated at 3, 6, 12, and 18 months after
the index date [1]. Adequate medication adherence was
defined as an MPR or PDC C0.8 [21]. Persistence was also
calculated, defined as continuous use of the index medi-
cation without a gap of C30 days between medication
refills, that is, between the end of the days of supply of a
dispensing and the following dispensing, at any time after
treatment initiation [20]. When an overlap occurred
between a new dispensing and the end of the previous
dispensing, and this overlap was no more than seven days,
the assumption was made that the prior supply was taken
fully before the initiation of the new supply. If an overlap
of more than 7 days occurred between two dispensings, no
adjustment was made and the second medication was
considered as initiated immediately.
2.4 Statistical Analyses
Univariate descriptive statistics were generated for the OD
and BID groups. Frequency counts and percentages were
used to summarize categorical variables. Mean values ±
SD were used to present normally distributed continuous
variables. Data that are often skewed such as costs were
reported with medians and interquartile ranges (median,
Q1–Q3). Statistical differences between both populations
were assessed using Chi-square tests (categorical variables)
and Student’s t tests (continuous variables). Nonparametric
statistics (i.e., Wilcoxon signed-rank test) were estimated
for the analysis of skewed variables. Kaplan–Meier esti-
mates and log-rank tests were performed to compare the
persistence rates at different points in time (3, 6, 12, and
18 months).
Multivariate logistic regressions were also conducted to
compare the probability of adherence between the OD and
BID groups adjusting for observation period, age, gender,
regions, year of index date, index medication (antidiabet-
ics, angiotensin-converting enzyme [ACE] inhibitors/
angiotensin receptor blockers [ARBs], calcium channel
blockers, diuretics, or beta-blockers), Charlson Comorbid-
ity Index, baseline pill burden (number of pills per day [the
number of pills dispensed during the 180-day baseline
period divided by 180 days] and number of different drug
entities), co-pay amount per dispensing, baseline health-
care costs (hospitalizations, outpatient visits, emergency
room visits, and pharmacy dispensings), and baseline dia-
betes and hypertension diagnosis.
Furthermore, stratified analyses were conducted on the
study population based on the type of VTE at baseline
(DVT only or PE with or without DVT). A two-sided alpha
level of 0.05 was used to declare statistical significance. All
statistical analyses were performed using SAS version 9.1
(SAS Institute, Inc., Cary, NC, USA).
3 Results
3.1 Patient Characteristics
A total of 4,867 OD and 1,069 BID patients with VTE
initiating antidiabetic or antihypertensive medications met
the inclusion criteria and formed the study populations
(Fig. 1). Table 1 describes the baseline characteristics of
the study populations. The mean age (median; SD) for the
OD and the BID group was 52.2 (50; 12.2) and 49.1
(50; 12.9) years, respectively (p \ 0.001); 54.3 and 53.0 %
were females, respectively (p = 0.453). The index drug
was mainly hypertension medications for both the OD
(94.4 %) and the BID groups (72.8 %).
3.2 Treatment Patterns and Medication Adherence
Table 2 presents the treatment patterns and medication
adherence of the OD and BID groups during the observa-
tion period. The mean (SD) duration of exposure to therapy
for OD and BID patients was 386 (366) and 356 (345) days
(p = 0.011), respectively.
Based on the MPR measurement, 69.2 % of OD patients
and 62.2 % of BID patients were adherent (i.e., MPR C0.8;
p \ 0.001). For PDC at 12 months, the proportion of
adherent patients (i.e., PDC C0.8) for the OD and BID
groups was 44.7 and 36.3 %, respectively (p \ 0.001).
Other PDC measurements at 3, 6, 12, and 18 months were
all significantly higher for the OD group relative to the BID
group (OD vs. BID; 3 months: 64.2 vs. 57.8 %; 6 months:
53.8 vs. 46.2 %; 18 months: 40.5 vs. 30.1 %; all p values
\0.001). The Kaplan–Meier rates of persistence to the
index medication assessed from months 3 to 18 were all
significantly higher (except the comparison at 3 months)
for the OD group compared with the BID group, with rates
from 68.5 to 31.1 % and 66.1 to 24.9 %, respectively.
Figure 2 summarizes the results of the multivariate
analyses comparing the probability of adherence between
the OD and BID groups after adjusting for baseline con-
founding factors. The adjusted odds ratio (95 % CI) of
adherence for the OD relative to BID group based on the
MPR definition was 1.61 (1.37–1.89). Based on the PDC
definition, the adjusted odds ratios (95 % CI) at 3, 6, 12,
and 18 months were 1.39 (1.18–1.64), 1.41 (1.18–1.69),
1.46 (1.16–1.83), and 1.51 (1.13–2.01), respectively. The
odds ratio findings showed that patients initiated on OD
dosing regimens were associated with a 39–61 % higher
likelihood of medication adherence than patients initiated
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on BID dosing regimens. Table 3 presents the complete
regression model estimates for the MPR measurement.
Since an ITT approach was used in the current study,
patients were allowed to switch dosing frequency within
the drug class of the index medication. Among the OD
cohort, 7.4 % of patients switched at least once to a BID
medication during the follow-up period, while in the BID
group 18.4 % of patients switched at least once to a OD
medication (p \ 0.001). The proportion of patients who
switched dosing frequency during the follow-up period is
reported in Table 4.
3.3 Stratified Analysis by Type of VTE
A total of 3,179 OD and 645 BID patients with DVT, and a
total of 1,688 OD and 424 BID patients with PE formed the
study populations of the stratified analysis. Table 5 pre-
sents the treatment patterns and medication adherence for
the stratified analysis. Based on the MPR, patient adher-
ence was higher for OD regimens as opposed to BID reg-
imens in both subsets (DVT group: 68.0 vs. 61.2 %,
p = 0.003; PE group: 71.4 vs. 63.7 %, p = 0.002). With
the PDC measurements at 3, 6, 12, and 18 months, a sta-
tistically higher medication adherence was found for the
DVT subset for the OD compared with the BID group. For
PE patients, although the adherence was higher for OD
patients compared with BID patients with corresponding
PDC measurements, statistical significance was only
reached for the comparison at 6 months. Of note, the
number of PE patients for the PDC measurements was
much lower compared with the overall and the DVT subset
analysis.
The adjusted odds ratios for the OD and BID group
comparison stratified by type of VTE are presented in
Fig. 2, while the complete regression model estimates for
the MPR measurements are reported in the Electronic
Supplementary Material. As measured by the MPR, DVT
and PE patients treated with OD dosing regimens were
both 62 % more likely to adhere to treatment than those
treated with BID dosing regimens, respectively (p \ 0.001
for both comparisons). PDCs at 3, 6, 12, and 18 months
revealed a higher likelihood of adherence among DVT
1. At least one prescription with a days of supply ≥28 days. 






≥2 OD dispensings ≥2 BID dispensings
≥1 VTE diagnosis at baseline ≥1 VTE diagnosis at baseline
174,2=N282,01=N
Patients naïve to other diabetes or 
HTN agents
Patients naïve to other diabetes or HTN 
agents
931,12=N255,201=N
At least 18 years old with ≥180 days of 
baseline eligibility
At least 18 years old with ≥180 days of 
baseline eligibility
621,8=N680,93=N
OD diabetes or HTN oral 
drugs users1,2 
BID diabetes or HTN oral 
drugs users1,2
Continuously enrolled with ≥1 VTE diagnosis 
N=281,760
Diabetes or HTN oral drugs (OD or BID) users
N=133,011
Fig. 1 Patients’ disposition
flow chart. BID twice daily,
DVT deep vein thrombosis,
HTN hypertension, OD once-
daily, PE pulmonary embolism,
VTE venous thromboembolism
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Table 1 Patient characteristics of the OD and BID study groups
Patient characteristics OD group BID group p value
Number of patients, n 4,865 1,069
Observation period, days, mean (±SD) 509.21 (420) 472.99 (385) 0.006
Demographics
Age at index date, mean (±SD) [median] 52.2 (12.2) [50.0] 49.1 (12.9) [50.0] \0.001
Female, n (%) 2,642 (54.3) 567 (53.0) 0.453
Region, n (%)
Northeast 1,243 (25.5) 241 (22.5) 0.065
South 1,117 (23.0) 230 (21.5)
Midwest 1,996 (41.0) 475 (44.4)
West 509 (10.5) 123 (11.5)
Year of index date, n (%)
2004 351 (7.2) 75 (7.0) 0.623
2005 789 (16.2) 156 (14.6)
2006 914 (18.8) 201 (18.8)
2007 1,081 (22.2) 230 (21.5)
2008 1,096 (22.5) 264 (24.7)
2009 634 (13.0) 143 (13.4)
Index medication, n (%)
Diabetes medications 273 (5.6) 291 (27.2)
Biguanides 125 (2.6) 227 (21.2) \0.001
Sulfonylurea 71 (1.5) 31 (2.9)
Thiazolidinedione 55 (1.1) 6 (0.6)
Other diabetes medications 22 (0.5) 27 (2.5)
Hypertension medications 4,592 (94.4) 778 (72.8)
ACE inhibitors/ARBs 1,643 (33.8) 103 (9.6) \0.001
Beta-blockers 920 (18.9) 498 (46.6)
Calcium channel blockers 505 (10.4) 28 (2.6)
Diuretics 1,524 (31.3) 149 (13.9)
Charlson comorbidity indexa, mean (±SD) 1.46 (2.33) 1.99 (2.6) \.001
Charlson comorbidity index distributiona, n (%)
0 2,313 (47.5) 346 (32.4)
1 1,106 (22.7) 299 (28.0)
2 591 (12.1) 164 (15.3)
3 288 (5.9) 72 (6.7)
4 153 (3.1) 52 (4.9)
5 or more 414 (8.5) 136 (12.7)
Other conditiona
Hypertension 2,254 (46.3) 399 (37.3) \0.001
Diabetes 546 (11.2) 240 (22.5) \0.001
Baseline pill burdena, n (%)
Mean number of pills per dayb
0 804 (16.5) 210 (19.6) 0.073
[0–1 1,401 (28.8) 317 (29.7)
[1–2 802 (16.5) 171 (16.0)
[2–3 510 (10.5) 96 (9.0)
[3 1,348 (27.7) 275 (25.7)
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Table 2 Treatment patterns,
adherence and persistence for
overall population
a The exposure to therapy was
defined as the number of days
between the first dispensing and
the last dispensing plus the days of
supply of the last refill
BID twice daily, MPR medication
possession ratio, OD once-daily,
PDC proportion of days covered
Variables OD group (N = 4,865) BID group (N = 1,069) p value
Treatment patterns, mean (±SD)
Exposure to therapya, days 386.4 (366) 356.4 (345) 0.011
Number of dispensings per patient 9.4 (9.85) 8.9 (9.51) 0.119
Days of supply per dispensing 35.1 (18.65) 33.1 (15.98) \0.001
Mean co-pay amount per prescription, US$ 12.4 (17.15) 10.7 (18.57) 0.006
Mean co-pay amount per prescription, n (%)
\US$10$ 2,954 (60.69) 681 (63.7) \0.001
US$10–24 1,240 (25.48) 308 (28.81)
US$25–39 378 (7.77) 43 (4.02)
CUS$40 295 (6.06) 37 (3.46)
Adherence
Based on exposure perioda
MPR, mean [median] 0.82 [0.91] 0.80 [0.88] 0.001
% compliant patients (MPR C0.8) 69.2 62.2 \0.001
At 3 months (n = 2,415; n = 487)
PDC, mean [median] 0.83 [0.93] 0.80 [0.88] \0.001
% compliant patients (PDC C0.8) 64.2 57.8 \0.001
At 6 months (n = 1,497; n = 276)
PDC, mean [median] 0.73 [0.83] 0.70 [0.76] 0.002
% compliant patients (PDC C0.8) 53.8 46.2 \0.001
At 12 months (n = 741; n = 130)
PDC, mean [median] 0.65 [0.74] 0.60 [0.66] 0.003
% compliant patients (PDC C0.8) 44.7 36.3 \0.001
At 18 months (n = 417; n = 59)
PDC, mean [median] 0.60 [0.66] 0.56 [0.61] 0.043
% compliant patients (PDC C0.8) 40.5 30.1 \0.001
Persistence, %
3 months 68.5 66.1 0.108
6 months 53.6 46.2 \0.001
12 months 38.1 32.3 \0.001
18 months 31.1 24.9 \0.001
Table 1 continued
Patient characteristics OD group BID group p value
Number of different drug entitiesc
0 804 (16.5) 210 (19.6) 0.049
1 3,033 (62.3) 627 (58.7)
2 704 (14.5) 152 (14.2)
3 or more 324 (6.7) 80 (7.5)
Baseline healthcare costsa, US dollars, mean (Q1|Med|Q3)
Hospitalizations 14,685 (0|0|10,757) 31,282 (0|4,773|23,763) \0.001
Pharmacy dispensings 1,243 (11|202|909) 1,072 (3|171|834) 0.195
Emergency room visits 404 (0|0|263) 520 (0|0|345) 0.170
Outpatient visits 6,100 (432|1,597|4,613) 6,351 (385|1,555|5,112) 0.634
a Based on the 180-day baseline period prior to the index date
b Defined as the total number of pills dispensed during the 180-day baseline period divided by 180 days for each patient
c Defined as the mean number of different brands per patient dispensed during the 180-day baseline period
ACE angiotensin-converting enzyme, ARBs angiotensin receptor blockers, BID twice daily, Med median, OD once-daily, Q1 interquartile 1, Q3
interquartile 3
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patients with OD dosing regimens over BID dosing regi-
mens of 45 % (p \ 0.001), 48 % (p \ 0.001), 68 %
(p \ 0.001), and 70 % (p = 0.006), respectively. Among
PE patients, the likelihood of adherence at 3, 6, 12, and
18 months was also greater for the OD versus BID patients;
however, most of the PDC measurements did not reach
statistical significance.
4 Discussion
Pharmacotherapy complexity is associated with reduced
medication adherence [22]. Compared with the general
population, VTE patients often have extensive operative
procedures and a higher disease burden [17, 18], and they
are also susceptible to experiencing various VTE-related
adverse events such as VTE recurrence, post-thrombotic
syndrome, and pulmonary hypertension [23–26]. The VTE
population is thus susceptible to experiencing various
adverse events that may be prevented by choosing treat-
ments that will reduce therapy complexity.
In this large retrospective study based on real-world
data, we found that VTE patients treated with OD therapy
had a 39–61 % higher likelihood of medication adherence
compared with comparable subjects on BID regimens,
regardless of whether MPR or PDC was used as the defi-
nition for adherence. Using an intent-to-treat approach, this
study allowed VTE patients to change daily dosing fre-
quency during the follow-up to represent real-world usage
of a patient initiating OD and BID regimens. Despite the
possible change in daily dosing regimens, patients initiat-
ing a OD treatment were more likely to be adherent
1. An adjusted odds ratio greater than one indicates that patients treated with OD dosing regimens were 
associated with a higher rate of medication adherence than those initiated on BID regimens after adjusting for 
baseline confounding factors. For example, an adjusted odds ratio of 1.20 indicates that patients in the OD group 
had a 20% higher likelihood of medication adherence compared with patients initiated on BID regimens. The 
horizontal bars represent the 95% confidence intervals
2. Confounding factors adjusted for in the multivariate logistic regression models included the follow-up period 
age, gender, regions, year of index date, index drug (antidiabetics, antihypertensives, calcium channel blockers, 
diuretics, or other hypertension medications), Charlson comorbidity index (categorical variable), diabetes and 
hypertension at baseline, baseline pill burden (number of pills per day and number of different drug entities), co- 
pay amount per dispensing (categorical variables), and baseline healthcare costs (hospitalizations, outpatient 
visits, emergency room, and pharmacy dispensings) 
0.5     0.75      1      1.25     1.5     1.75      2      2.25     2.5
Adjusted Odds Ratios1,2
BID more adherent OD more adherent
MPR
PDC at 3 months
PDC at 6 months
PDC at 12 months
PDC at 18 months
Overall OD and BID Populations
MPR
PDC at 3 months
PDC at 6 months
PDC at 12 months
PDC at 18 months
DVT OD and BID Populations
MPR
PDC at 3 months
PDC at 6 months
PDC at 12 months
PDC at 18 months
PE OD and BID Populations
Fig. 2 Multivariate logistic regressions modeling the adjusted probability of adherence for the OD relative to BID group. BID twice daily, DVT
deep vein thrombosis, MPR medication possession ratio, OD once-daily, PDC proportion of days covered, PE pulmonary embolism
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compared with BID users. This finding was robust over
time (3–18 months) and was observed with both MPR and
PDC methods. Similar trends were also observed in strat-
ified analyses by type of VTE (DVT only or PE with and
without DVT).
Hypertension and diabetes are relatively ‘silent’ (i.e.,
asymptomatic) diseases, while VTE patients treated with
anticoagulation medication, on the other hand, typically
have symptomatic disease (proximal DVT or PE) and they
are often well aware of the possible serious short-term
consequences (e.g., VTE recurrence) of not taking their
anticoagulant medication. However, even if the adherence
to the initial treatment of a VTE event (e.g., parenteral
anticoagulant) might be higher, patients are usually dis-
charged from hospital with a prescription of oral antico-
agulant to reduce the incidence of recurrent VTE, and the
longer-term adherence to therapy post-discharge is a con-
cern in the VTE community. An article by Ganz and col-
leagues [12] showed that nearly a quarter of anticoagulated
patients following DVT or PE received therapy for less
than the recommended length of time after hospital dis-
charge. Deitelzweig and colleagues [13] found that 12 % of
patients discontinued warfarin within 3 months and treat-
ment discontinuation was identified as a significant pre-
dictor of recurrent VTE. Of note, a life-threatening
condition such as PE might lead to a better adherence from
patients. In the study by Ganz and colleagues [12], PE
patients were less likely to have inadequate duration of
therapy in comparison with those with DVT (odds ratio
0.58, 95 % CI 0.38–0.88). Considering the asymptotic
nature of diabetes and hypertension, the current study on
the adherence to antihypertensive and antidiabetic drugs
only allowed indirect conclusions to be drawn regarding
VTE patients’ adherence to other chronic medications.
Further research is warranted to assess if a better adherence
for OD versus BID medication is found for other types of
medications in VTE patients and if there is a difference
between DVT and PE patients.
In the current study, around 20 % of the population was
initiated on BID therapy, which is an important proportion
of chronic drug users. This study highlighted the difference
in adherence among VTE patients using OD and BID
chronic medications, which could have an impact on pos-
sible adverse events related to non-adherence. Further
research will be required to examine the impact of adher-
ence on clinical outcomes. Non-adherence can cause
adverse outcomes such as relapse of the disease being
treated, nursing home admission, and hospitalization [27–
30], and it has been estimated that 33–69 % of all medi-
cation-related hospital admissions are due to poor medi-
cation adherence [27]. Of note, adherence with OD
regimens was also suboptimal in the current study.
Adherence is a multifactorial process and changing the
Table 3 Multivariate analysis: logistic regression model—modeling
the probability of adherence (MPR C80 %)a
Variables Odds
ratio
95 % CI p value
Study groups
OD (ref.: BID)—unadjusted 1.36 1.19–1.56 \0.001
OD (ref.: BID)—adjusted 1.61 1.37–1.89 \0.001
Observation period (years: continuous) 0.69 0.66–0.73 \0.001
Demographics
Age (years: continuous) 1.02 1.01–1.02 \0.001
Female (ref: male) 0.87 0.78–0.98 0.025
Region (ref.: Northeast)
South 0.90 0.76–1.06 0.200
Midwest 1.24 1.07–1.44 0.004
West 1.13 0.91–1.40 0.264
Year of index date (ref.: 2009)
2004 0.63 0.47–0.84 0.002
2005 0.83 0.65–1.07 0.156
2006 0.80 0.63–1.02 0.072
2007 0.71 0.57–0.89 0.003
2008 0.70 0.56–0.87 0.001
Index drug (ref.: beta-blockers)
Antidiabetics 0.83 0.65–1.05 0.124
ACE inhibitors/ARBs 0.95 0.80–1.13 0.550
Calcium channel blockers 1.02 0.80–1.31 0.844
Diuretics 0.53 0.45–0.63 \0.001
Charlson comorbidity indexb (ref.: 0)
1 0.89 (0.76–1.03) 0.118
2 1.14 (0.94–1.38) 0.199
3 0.91 (0.70–1.18) 0.483
4 0.83 (0.59–1.17) 0.277
5 or more 1.09 (0.85–1.41) 0.497
Other comorbiditiesb
Diabetes 1.09 (0.88–1.33) 0.431
Hypertension 0.97 (0.86–1.10) 0.656
Baseline pills burdenb (continuous)
Number of pills per day 1.02 (1.00–1.03) 0.078
Number of different drug entities 0.99 (0.93–1.06) 0.766
Co-pay amount per prescription (ref: \US$10)
US$10–24 1.16 1.01–1.34 0.033
US$25–39 1.06 0.84–1.34 0.627
CUS$40 1.16 0.88–1.52 0.286
Baseline healthcare costsb (US$000;
continuous)
Hospitalizations 1.00 1.00–1.01 \0.001
Pharmacy prescriptions 0.99 0.98–1.01 0.449
Emergency room visits 0.98 0.95–1.02 0.343
Outpatient visits 1.00 0.99–1.00 0.463
ACE angiotensin-converting enzyme, ARBs angiotensin receptor blockers,
BID twice a day, MPR medication possession ratio, OD once a day
a The Hosmer and Lemeshow goodness of fit p value is 0.571, suggesting
that the fitted model is an adequate model
b Based on an observation period of 180 days prior to index date
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dosing frequency can only partially improve adherence.
Factors that may affect patient adherence have been clas-
sified as modifiable or nonmodifiable [31]. Nonmodifiable
factors include the asymptomatic nature of a disease that
may cause patients to forget about their condition, while
modifiable factors include the number of medications
prescribed, daily dosing frequency, and complexity of
administration (e.g., parenteral, oral). A multi-faceted
approach to improving adherence is thus needed.
Recent studies have evaluated the medication adherence
to OD relative to BID regimens using administrative claims
[32–34]. Bae and colleagues [32] used administrative
claims data from July 2006 to December 2008 to evaluate
medication adherence to antidiabetic, antihyperlipidemic,
antiplatelet, or cardiac agent therapy in more than 1 million
patients. They found that a OD dosing regimen was related
to a 16 % higher MPR versus a BID regimen, with mean
MPR of 0.66 and 0.57, respectively (p \ 0.01). A study by
Toy and colleagues [33] using an administrative claims
database from 1999 to 2006 showed that medication
adherence to the initial drug treatment of chronic
obstructive pulmonary disease (COPD) was associated
with dosing frequency, with OD dosing having the highest
adherence levels relative to BID, TID, or QID. Based on a
sample of 55,076 COPD patients over 12 months of fol-
low-up, the PDC was 43.3, 37.0, 30.2, and 23.0 % for OD,
BID, TID, and QID cohorts, respectively. The authors also
showed a 22–26 % significantly higher likelihood of
adherence to a OD compared with BID dosing regimen
among patients with nonvalvular atrial fibrillation in a
previous study [34].
The impact of OD versus BID regimens on medication
adherence has also been evaluated in two recent meta-
analyses of studies using electronic monitoring devices [10,
11]. Coleman and colleagues [10] reviewed the effect of
dosing frequency on chronic cardiovascular disease medi-
cation adherence and found that adjusted mean adherences
to BID and TID regimens was significantly lower by
7–23 % and 14–30 % (depending on the method used to
determine adherence), respectively, compared with OD
regimens. Coleman and colleagues also studied medication
adherence in patients with chronic diseases and found that
adjusted mean adherence to BID, TID, and QID regimens
was significantly lower by 7–27 %, 14–39 %, and
19–54 %, respectively, compared with a OD regimen [11].
Review articles have studied the impact of OD versus BID
regimens on medication adherence, although most of the
underlying data for these studies are based on the pre-2000
era. A systematic review by Saini and colleagues [35] on
adherence in asymptomatic chronic disease, as assessed by
medication event monitoring systems, reported that
patients were more compliant with OD compared with BID
regimens. Patients receiving OD dosing had 2–44 % more
adherent days compared with patients receiving BID dos-
ing, with most studies clustering around 13–26 %; how-
ever, because of differences in study design, study
population, and data reporting no attempt was made to
combine these results into a meta-analysis. Iskedjian and
Table 4 Daily dosing frequency switches within the drug class of the index medication for the OD and BID study groups
Daily dosing frequency change during the follow-up period OD group BID group p value
C1 BID (OD group) or C1 OD (BID group), % [A] 358/4,867 (7.36 %) 197/1,069 (18.43 %) \0.001
0–3 months 172/4,867 (3.53 %) 85/1,069 (7.95 %) \0.001
4–6 months 162/3,602 (4.50 %) 97/790 (12.28 %) \0.001
7–12 months 165/2,777 (5.94 %) 95/592 (16.05 %) \0.001
13–18 months 122/1,725 (7.07 %) 77/357 (21.57 %) \0.001
C1 TID or QID, % [B] 75/4,867 (1.54 %) 85/1,069 (7.95 %) \0.001
0–3 months 33/4,867 (0.68 %) 49/1,069 (4.58 %) \0.001
4–6 months 46/3,602 (1.28 %) 45/790 (5.70 %) \0.001
7–12 months 40/2,777 (1.44 %) 43/592 (7.26 %) \0.001
13–18 months 17/1,725 (0.99 %) 39/357 (10.92 %) \0.001
C1 different daily dosing frequency, % ([A] or [B]) 405/4,867 (8.32 %) 275/1,069 (25.72 %) \0.001
0–3 months 200/4,867 (4.11 %) 134/1,069 (12.54 %) \0.001
4–6 months 198/3,602 (5.50 %) 142/790 (17.97 %) \0.001
7–12 months 194/2,777 (6.99 %) 138/592 (23.31 %) \0.001
13–18 months 137/1,725 (7.94 %) 113/357 (31.65 %) \0.001
[A] switch within the drug class of the index medication to a BID (OD group) or to a OD (BID group) medication, [B] switch within the drug
class of the index medication to a TID or a QID medication
BID twice a day, OD once a day, QID four times a day, TID three times a day
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colleagues [30] conducted a meta-analysis and demon-
strated that with antihypertensive medications, OD dosing
therapy compared with either BID or multiple daily dose
therapy was associated with higher rates of medication
adherence. A systematic review by Claxton and colleagues
[36] of studies reporting adherence measured by electronic
monitoring devices, including published reports on several
conditions (e.g., cardiovascular disease, respiratory dis-
ease, infectious disease, and cancer), reported that medi-
cation adherence was inversely proportional to dosing
frequency. Adherence was significantly higher for OD
versus TID and for OD versus QID regimens; however,
there were no significant differences in adherence between
OD and BID regimens.
Table 5 Treatment patterns, adherence and persistence for DVT and PE patients










Treatment patterns, mean (±SD)
Exposure to therapy, days 388.64 (362) 367.31 (347) 0.170 382.16 (372) 339.77 (341) 0.025
Number of dispensings per
patient
9.42 (9.70) 9.22 (9.76) 0.646 9.44 (10.12) 8.43 (9.11) 0.046
Days of supply per dispensing 35.47 (18.91) 32.99 (16.16) \0.001 34.55 (18.12) 33.30 (15.71) 0.158
Mean co-pay amount per
prescription
12.76 (17.64) 10.91 (20.74) 0.034 11.62 (16.18) 10.30 (14.69) 0.105
Mean co-pay amount per prescription, n (%)
\US$10 1,904 (59.89) 400 (62.02) \0.001 1,050 (62.2) 281 (66.27) 0.102
US$10–24 816 (25.67) 201 (31.16) 424 (25.12) 107 (25.24)
US$25–39 254 (7.99) 21 (3.26) 124 (7.35) 22 (5.19)
US$C40 205 (6.45) 23 (3.57) 90 (5.33) 14 (3.3)
Adherence
Based on exposure period
MPR, mean [median] 0.82 [0.90] 0.79 [0.87] 0.008 0.84 [0.93] 0.81 [0.89] 0.037
% compliant patients
(MPR C0.8)
68.0 61.2 0.003 71.4 63.7 0.002
At 3 months (n = 2,882; n = 583 | n = 1,496; n = 384)
PDC, mean [median] 0.82 [0.93] 0.79 [0.87] 0.003 0.84 [0.94] 0.81 [0.89] 0.011
% compliant patients
(PDC C0.8)
63.3 55.9 0.002 65.8 60.7 0.059
At 6 months (n = 2,407; n = 493 | n = 1,225; n = 295)
PDC, mean [median] 0.73 [0.83] 0.69 [0.76] 0.012 0.73 [0.83] 0.70 [0.78] 0.055
% compliant patients
(PDC C0.8)
53.7 45.2 0.005 54.6 47.8 0.035
At 12 months (n = 1,660; n = 338 | n = 854; n = 194)
PDC, mean [median] 0.64 [0.74] 0.59 [0.66] 0.008 0.65 [0.74] 0.61 [0.65] 0.159
% compliant patients
(PDC C0.8)
45.5 36.1 0.006 43.3 36.6 0.087
At 18 months (n = 1,157; n = 208 | n = 614; n = 141)
PDC, mean [median] 0.60 [0.66] 0.56 [0.63] 0.107 0.60 [0.66] 0.57 [0.57] 0.208
% compliant patients
(PDC C0.8)
41.2 29.3 0.002 39.3 31.2 0.076
Persistence, %
3 months 67.5 65.6 0.250 70.0 67.0 0.204
6 months 53.5 45.5 0.002 53.7 47.3 0.037
12 months 37.9 31.2 0.002 38.4 34.0 0.077
18 months 31.1 24.7 0.002 31.0 25.1 0.038
BID twice daily, DVT deep vein thrombosis, MPR medication possession ratio, OD once-daily, PDC proportion of days covered, PE pulmonary
embolism
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Other review articles of literature published between the
1970s and the 1990s could not reach a definitive conclusion
on whether the simplification of dosing regimens was
associated with better medication adherence [37–40]. The
current study concurs with the most recent literature that
patients were more compliant with OD compared with BID
regimens [10, 11, 30, 32–35]. More up-to-date studies are
warranted on the impact of daily dosing regimens on
adherence given the serious consequences of nonadherence
to chronic medications, such as hospital readmission [27]
and other adverse outcomes.
This study was subject to several limitations. First,
claims databases may contain inaccuracies or omissions in
coded procedures, diagnoses, or pharmacy claims; however,
it would be unlikely that these have significantly impacted
our results considering the large sample size. Second,
adherence to OD and BID regimens were assessed based on
PDC, which may not reflect patients’ actual adherence to
medications. A claim for a prescription refill does not
necessarily mean that a patient is taking the medication as
prescribed, as some patients may obtain refills before a
prescription runs out. However, in the current study if a
claim for a new prescription overlapped with the end of the
previous supply within a 7-day window, the beginning of
the new prescription was delayed in order to minimize the
early refill effect. Third, although we conducted multivari-
ate analyses to account for baseline confounding factors
between the OD and BID groups, omitted variable bias
cannot be ruled out. For example, the current study used
only prescribed medications since over-the-counter medi-
cations were not available in the database. Consequently, it
was not possible to control for the impact that over-the-
counter medication usage might have had on adherence
levels. In addition, since the exposure to OD or BID med-
ication was not randomly selected, there is the possibility of
confounding by indication. Despite these limitations, well
designed retrospective studies provide valuable informa-
tion, with real-life scenarios and high generalizability.
5 Conclusion
This large real-world study of nearly 6,000 patients shows
that patients with a history of thromboembolism (at least
one primary or secondary diagnosis of VTE) treated with
OD dosing regimens for chronic medications were asso-
ciated with an approximately 39–61 % higher likelihood of
adherence to therapy compared with subjects on BID
dosing regimens. The findings were consistent across two
methods of determining medication adherence.
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